SCCS Final Opinion on HAA299 (Nano)
HAA299 (non-nano) has been used in cosmetic products as a UV filter. In 2014, the SCCS considered that this ingredient in its non-nano form was safe for use as a UV-filter in cosmetics, at a maximum concentration of 10%. The SCCS released its final opinion regarding the use of HAA299 in its nano form.
Marta Pinto

Marta Pinto

Regulatory Affairs Associate

HAA299 AND ITS SAFETY

HAA299 (CAS number: 919803-06-8), also called Bis-(Diethylaminohydroxybenzoyl Benzoyl) Piperazine (INCI name) is an organic compound used as a UV-filter in cosmetics and personal care products. HAA299 (nano form and non-nano) is not currently included in the Annexes of the European Cosmetics Regulation (Regulation (EC) No 1223/2009).

In 2014, the European Commission’s Scientific Committee on Consumer Safety (SCCS) issued an opinion regarding the use of HAA299 as UV filter in sunscreen products. The SCCS concluded that the use of non-nano HAA299 (micronized or non-micronized, with median particle size distribution around 134 nm or larger) at a concentration up to 10% as an UV-filter in cosmetic products, does not pose a risk of systemic toxicity in humans. The SCCS safety evaluation does not apply to inhalation exposure and covered only the HAA299 in the non-nano form, not covering when this ingredient is composed of nano particles.

HAA299 has low oral bioavailability and scientific evidence shows an overall very low or lack of dermal absorption of HAA299 in human skin. Non-micronized HAA299 was not a dermal irritant when applied in rabbits but it caused slight irritation in the eyes of rabbits. No delayed contact hypersensitivity was observed in a murine Local Lymph Node Assay (LLNA), but the sensitization potential of HAA299 could not be ruled out by the SCCS. Phototoxicity studies with HAA299 indicate that this ingredient has no phototoxic, photoallergic or photogenotoxic potential.

NEW SCCS OPINION ON HAA299 (NANO-FORM)

The SCCS released its new opinion regarding the safety of HAA299 in its nano-form (aqueous dispersion of nanoparticles formulation with excipients containing the HAA299 active UV filter ingredient that was micronized to nano size).

The available data indicated that HAA299 in the nano-form is a practically insoluble material, with very low dermal and oral absorption. Nano HAA299 did not show skin irritation potential or caused ocular corrosion or severe ocular irritation in in vitro tests. Skin sensitizing and phototoxic potential are considered unlikely.

The SCCS expressed concerns regarding the repeated use of products containing nano HAA299, due to the inflammatory effects on the lung after acute inhalation exposure. The Committee does not recommend the use of this ingredient in applications that could lead to exposure of the consumer’s lungs via inhalation.

Considering the currently available scientific evidence, which shows an overall very low or lack of dermal absorption of nano HAA299, the SCCS considers that “HAA299, either as non-nano or nano form, is safe when used as a UV-filter in dermally-applied cosmetic products up to a maximum concentration of 10%”. Moreover, the Committee indicated that the combined maximum concentration of the two forms (nano and non-nano) should not exceed 10% in cosmetic products.

The SCCS may consider the revision of its opinion if new evidence emerges in the future to show that nano HAA299 used as UV-filter in cosmetic products can penetrate human skin to reach viable cells in higher levels than demonstrated in the submission.

If you wish to get more information on the safety of cosmetic ingredients, feel free to contact us at info@criticalcatalyst.com.

References:

  1. Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products.
  2. Scientific Committee on Consumer Safety (SCCS). Opinion on HAA299 (nano). SCCS/1634/21. 2021
  3. Scientific Committee on Consumer Safety (SCCS). Opinion on 2-(4-(2-(4-Diethylamino-2-hydroxy-benzoyl)-benzoyl)- piperazine-1-carbonyl)-phenyl)- (4-diethylamino-2- hydroxyphenyl)-methanone (HAA299) as UV filter in sunscreen products. SCCS/1533/14. 2014

further
reading

cosmetic products

The Responsible Person in the EU

Only cosmetic products for which a Responsible Person is designated in the European Union can be placed on the EU market. The Responsible Person must ensure full compliance with the European Cosmetic Regulation.

Read More »
cosmetic products

SCCS Preliminary Opinion on Genistein and Daidzein

The European Commission Scientific Committee on Consumer Safety (SCCS) has published its preliminary opinion on the use of Genistein and Daidzein in cosmetic products. The deadline for comments was set at 14 March 2022.

Read More »
cosmetic products

The Cosmetic Products Notification Portal (CPNP)

Only cosmetic products for which a legal or natural person is designated within the EU as a “Responsible Person” can be placed on the European Union (EU) market. Before placing a cosmetic product on the EU market, the RP must notify it in the Cosmetic Products Notification Portal (CPNP).

Read More »
cosmetic products

French Anti-Waste Law

The Loi relative à la lute contre le gaspillage et a l’économie circulaire (Anti-Waste for a circular economy) has come officially into force in France in 2020. Since the beginning of this year, some requirements of the law became mandatory, like the Triman logo. The law provides for a ban on all single-use plastics by 2040.

Read More »
cosmetic products

SCCS Preliminary Opinion on 4-MBC

In 2019, the European Commission set out two lists of ingredients suspected of having endocrine disrupting properties. As 4-MBC (UV-filter) was included in the higher priority group, the European Commission asked the SCCS to carry out a safety assessment on this ingredient. The preliminary version of the requested opinion was published.

Read More »
cosmetic products

SCCS Revision of the Opinion on Vitamin A

Vitamin A is not currently included in the Annexes of the European Cosmetics Regulation (Regulation (EC) No 1223/2009). The SCCS published the preliminary version of its revision of the scientific opinion on Vitamin A (retinol, retinyl palmitate and retinyl acetate). The deadline for comments was set at 7 February.

Read More »
medical devices

Person Responsible for Regulatory Compliance (PPRC) under MDR & IVDR

The EU Medical Device Regulation (EU MDR) and the EU In Vitro Diagnostic Device Regulation (EU IVDR) require all Manufacturers and Authorized Representatives to have a designated employee in their company who is responsible for regulatory compliance with the applicable MDR or IVDR requirements, the Person Responsible for Regulatory Compliance (PRRC).

Read More »